Lightning Talks Selectees
BARDA is pleased to announce the presenters for 2020 BARDA Industry Day Lightning Talks. We are in our third year of hosting Lighting Talks, as a means to incorporate our stakeholders into the Industry Day program and help companies network among our audience of top industry experts, government partners and BARDA team.
We were thrilled by the response to this year’s open call for submissions. Over 336 submissions were received, making the choices to narrow down our top presenters very challenging! After a careful review of the submissions, twenty were chosen to highlight their innovations. It was not an easy decision as many of the submissions were outstanding.
On October 27th, there will be two concurrent pre-recorded afternoon Lightning Talk Sessions. One focused on diagnostics and medical devices, and the other focused on vaccines and therapeutics.
Please find below the list of selected presenters for this year’s Lightning Talk sessions.
Diagnostics and Medical Device Session:
Vaccine and Therapeutics Session:
| Company | Title |
|---|---|
| Adaptive Biotechnologies | Understanding Immunity to SARS-CoV-2: The T Cell Side of the Equation |
| Instanosis Inc. | Ultransensitive SARS-CoV-2 Antigen Detection Using Microbubbling |
| MeMed | MeMed BV™/Key™: Responding Today, Preparing for Tomorrow. A Host-Protein Test for Combatting Antimicrobial Resistance Plus Biomarkers to Aid in Outbreak Management |
| The University of Kansas | Development of a Handheld Radiation Bio-Dosimeter for Point-of-Care Use |
| PhenoMx | Multi-Parametric Quantitative Whole-Body Assessment of COVID-19 Infected Individuals for Risk of Chronic Long-Term Conditions |
| Promethean LifeSciences | GammaGraft for Burn and Wound Medical Countermeasures Stockpiling |
| PharmaJet | Needle-free Delivery of Pandemic Vaccines |
| Vir Biotechnology, Inc | Immunological Tools for Pandemic Preparedness |
| Autonomous Therapeutics, Inc. | Non-Vaccine, Pan-Genus Prophylactics to Prevent COVID-19 and any Future Beta-Coronavirus Pandemic |
| Abimmune Biopharma Inc. | Respiviridin: A Universal Prophylactic & Therapeutic Candidate against Covid-19 and other Respiratory Viruses |
| Biomed Industries, Inc. | What does Covid-19 Virus do to the Brain? |
| Advanced Innovative Partners/Bio-Nucleonics | Treatment of COVID-19 Virus |
| HDT Bio Corp. | Development of RNA-based PAMP Plus LION as a Novel Antiviral Therapy to Limit COVID-19 |
| KAER Biotherapeutics Corporation | Therapeutic Surfactant and Biologics Aerosols for the Treatment of Hypoxemia and Respiratory Distress |
| Zim Biosciences Inc. | A Technology for the Amelioration of Thermal and/or Chemical Insults to Lung Tissue |
| VitriVax | Thermostable, Single-Shot Vaccine Formulation Platform |
| FluGen Inc. | M2SR Seroconversion Against H3N2 Proximate & Distant Drift |
| Virica Biotech Inc. | Viral Sensitizers: Accelerating Vaccine Production and Pandemic Response. |
| Codex DNA | Establishing a Global Network of Vaccine Printers |
| Persephone Biosciences | Arming the Immune System Using Gut Microbiome Therapeutics to Prevent and Fight SARS-CoV-2 |
